Finoriq research workspace
Arcutis Biotherapeutics, Inc. (ARQT) SEC Filings & Filing Highlights
Arcutis Biotherapeutics, Inc. also develops ZORYVE foam seborrheic dermatitis, and scalp and body. Review ARQT SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Company
- Arcutis Biotherapeutics, Inc. (ARQT)
- Ticker
- ARQT
- Market Cap
- $3.5B
- Latest Price
- $27.76
- Industry
- Biotech & Pharma
Arcutis Biotherapeutics, Inc. (ARQT) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Arcutis Biotherapeutics, Inc. (ARQT).
| Event | Form | Date |
|---|---|---|
| Arcutis Biotherapeutics, Inc.: Corporate updateAs part of a regular review of the corporate governance practices of the Company and in an effort to continue to attract and retain qualifi... | 8-K8.01 | 2026-06-09 |
| Proposal 1. The election of three Class III directors to hold office until the 2029 annual meet...On June 5, 2026, Arcutis Biotherapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the... | 8-K5.07 | 2026-06-09 |
| Cover Page Interactive Data FileCover Page Interactive Data File (formatted as Inline XBRL) | 8-K9.01 | 2026-05-06 |
| Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Upd...Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 8-K2.02 | 2026-02-25 |
| Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retiremen...Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri | 8-K7.01 | 2025-12-08 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.